End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
790,000 KRW | -0.13% | +1.80% | +3.95% |
08:05am | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
07:19am | Samsung Biologics Posts Higher Q1 Profit, Sales | MT |
Sales 2024 * | 4,262B 3.1B | Sales 2025 * | 4,964B 3.61B | Capitalization | 56,227B 40.93B |
---|---|---|---|---|---|
Net income 2024 * | 1,015B 739M | Net income 2025 * | 1,201B 874M | EV / Sales 2024 * | 12.7 x |
Net cash position 2024 * | 1,882B 1.37B | Net cash position 2025 * | 2,940B 2.14B | EV / Sales 2025 * | 10.7 x |
P/E ratio 2024 * |
55.4
x | P/E ratio 2025 * |
48.1
x | Employees | 4,284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 25.25% |
1 day | -0.13% | ||
1 week | +1.80% | ||
Current month | -4.93% | ||
1 month | -5.95% | ||
3 months | +0.25% | ||
6 months | +7.05% | ||
Current year | +3.95% |
Managers | Title | Age | Since |
---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 17-12-31 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 11-04-20 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 2 M€ | -14.14% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 790,000 | -0.13% | 48,667 |
24-04-23 | 791,000 | -1.37% | 44,112 |
24-04-22 | 802,000 | +2.69% | 59,922 |
24-04-19 | 781,000 | -1.14% | 55,678 |
24-04-18 | 790,000 | +1.80% | 33,200 |
End-of-day quote Korea S.E., April 23, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.95% | 40.86B | |
-2.86% | 87.31B | |
-21.94% | 29.36B | |
+53.61% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
+1.35% | 8.31B | |
+2.09% | 7.63B |
- Stock Market
- Equities
- A207940 Stock